Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients by Ji Won Park et al.
RESEARCH ARTICLE Open Access
Comparison of the long-term efficacy
between entecavir and tenofovir in
treatment- naïve chronic hepatitis B
patients
Ji Won Park1,2, Kyeong Min Kwak3,4, Sung Eun Kim1, Myoung Kuk Jang5, Ki Tae Suk6, Dong Joon Kim6,
Sang Hoon Park7, Myung Seok Lee7, Hyoung Su Kim5* and Choong Kee Park1
Abstract
Background: There have been limited studies directly comparing the long-term efficacy between entecavir (ETV)
and tenofovir disoproxil fumarate (TDF). This study was aimed to compare the long-term efficacy between them in
treatment-naïve chronic hepatitis B (CHB).
Methods: Out of 345 CHB patients who received first line therapy with ETV (n = 200) or TDF (n = 145) in a cohort,
210 patients were analyzed using propensity score matching, at a ratio of 1:1.
Results: Two groups showed no difference in baseline characteristics. During the follow-up of 12 months, HBV DNA
levels were similarly suppressed in both groups (ETV vs. TDF; −5.01 vs. -5.242 log10IU/mL, P = 0.559). At month 12, both
groups showed no difference in terms of the serologic, biochemical and virologic (VR) response. In multivariate
analysis, the initial virologic response at 3 months (IVR-3) was independent factor for VR at 1 year. During the long-term
follow-up, HBV DNA levels were more strongly suppressed by TDF than ETV in hepatitis B e antigen (HBeAg) positive
patients (P = 0.035), especially with high viral load (P = 0.012), although there was no significant difference in overall VR
between two groups. The type of antivirals was not an independent factor for long-term VR.
Conclusions: Although either ETV or TDF, overall, may show a comparable long-term antiviral efficacy in
treatment-naïve CHB, TDF might be better regimen than ETV in the subgroup of HBeAg-positive CHB, especially
with a higher HBV DNA levels.
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Background
Approximately 350 million people are estimated to be
chronically infected with hepatitis B virus (HBV), which
may result in serious complications, such as hepatic
failure, advanced cirrhosis, and/or hepatocellular carcin-
oma (HCC) in 15–40% of patients [1–3]. In addition to
clinical host factors, such as age, family history, and
alcohol abuse, many HBV-related factors themselves,
which include HBV mutations of precore/core promoter
regions, HBV genotype C, and high serum HBV DNA
levels (viral factors), contribute to the critical progres-
sion of chronic liver diseases [4–6]. Although factors
such as mutations or genotypes are not changed by
antivirals, serum HBV DNA levels, e.g., HBV replication,
can be sustainably suppressed by anti-HBV therapies to
prevent and/or retard cirrhosis and subsequently HCC.
To date, oral antiviral drugs such as lamivudine,
adefovir, entecavir, telbivudine and tenofovir have been
widely used in clinical settings [4, 7, 8].
According to several international guidelines, entecavir
(ETV) or tenofovir disoproxil fumarate (TDF) are recom-
mended as first line therapy in the treatment of naïve CHB
because of their higher antiviral potency and higher genetic
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barriers than other antiviral agents [9–13]. In reality, ETV
and TDF showed high virologic responses of up to 93% and
100%, respectively, and a rare genotypic resistance of only
1.2% and 0%, respectively, during the 5- year follow-up in a
cohort study [14, 15].
Although there have been a few reports comparing the
short-term efficacy directly between TDF and ETV in
treatment-naïve CHB, there is still little available clinical
information about the long-term efficacy. Therefore, we
performed this study to compare the long-term efficacy
between TDF and ETV in treatment-naïve CHB patients.
Methods
Patients and study design
A total of 345 treatment-naïve CHB patients who received
a single regimen of either TDF (n = 145) or ETV (n = 200)
for at least 12 months were consecutively enrolled from 4
tertiary university hospitals in Korea between January
2011 and December 2014. Because TDF or ETV use was
not randomly assigned, potential confounding and selec-
tion biases were accounted for by developing a propensity
score. Among a total of 345 patients, 210 patients were
selected using propensity score match, at a ratio of 1:1.
Patients with the following characteristics were excluded:
1) other viral infections such as HCV, HDV and HIV, 2)
other concomitant liver diseases such as alcoholic liver
disease and autoimmune liver disease, or 3) HCC. Patients
were monitored by clinical examination and biochemical
and virologic assessments at least every 3 to 4 months
during the antiviral therapy.
The study protocol was approved by the Hallym
University Medical Center Institutional Review Boards
(IRB No. 13-1-49).
Serum assay and methodology
Biochemistry was performed using standard laboratory
procedures. Hepatitis B surface antigen (HBsAg), antibody
to HBsAg (anti-HBs), HBeAg, and antibody to HBeAg
(anti-HBe) were measured using microparticle enzyme
immunoassay (Abbott Laboratories, North Chicago, IL,
USA). Serum HBV DNA levels were measured using a
COBAS TaqMan PCR assay (Roche, Branchburg, NJ,
USA; lower limit of detection 20 IU/mL).
Definitions
Primary non-response was defined as a failure to reduce
serum HBV DNA levels by >1 log10 IU/mL after
3 months of therapy [16]. A high HBV DNA level was
defined as a serum HBV DNA level greater than 6 log10
IU/mL. Initial virologic response at 3 months (IVR-3)
and virologic response (VR) were defined as an HBV
DNA level <3.3 log10 IU/mL after 3 months of therapy
[17, 18] and an undetectable HBV DNA level (<20 IU/
mL) during the therapy, respectively. A biochemical
response was defined as a normalization of the serum
alanine aminotransferase (ALT) levels. Virologic break-
through (VBT) was defined as an increase over 1 log10
IU/mL of serum HBV DNA levels from the nadir during
the therapy or serum HBV DNA levels >200 IU/mL in
patients who experienced VR.
Statistical analyses
HBV DNA levels were logarithmically transformed for ana-
lysis. The Mann–Whitney U-test for continuous variables
and chi-squared test for categorical variables were used in
the analyses as appropriate. A repeated measures analysis
was used to compare HBV DNA reduction according to
the drug used. Cumulative VR and VBT rates were
calculated using the Kaplan-Meier method, and the differ-
ence was determined by a log-rank test. The multivariate
logistic regression model and Cox proportional hazards
model were used to identify the independent risk factors
significantly associated with short-term and long-term VR,
respectively. Candidate variables with a P value of < 0.1 on
univariate analysis were entered into the regression analysis.
A P-value of less than 0.05 was considered significant.
Statistical analyses were performed using SPSS, version 16
(SPSS, Inc, Chicago, IL).
To reduce and control any confounding factors before
receiving the treatment, we used the propensity scores
to match TDF users to ETV users. A macro (available at:
http://www2.sas.com/proceedings/sugi26/p214-26.pdf )
was used to develop the propensity scores.
Results
Baseline patient characteristics
Among 345 patients, the propensity-matched 105 patients
in each group were included (1:1). The baseline character-
istics of the study population are summarized in Table 1.
One hundred thirty one (62.4%) patients were men and
the mean age was 46.2 ± 12.0 years. Eighty four patients
(40%) had had cirrhosis and 121 patients (57.6%) were
positive for HBeAg. The mean HBV DNA levels and ALT
levels were 6.61 ± 1.30 log10 IU/mL and 205.9 ± 351.5 IU/
L, respectively. There was no difference in the baseline
characteristics between the TDF and ETV groups. On
average, patients were treated for 25.3 (12–39) months.
Therapeutic responses
Figure 1 shows the changes in the mean HBV DNA levels
during the first 12 months. Overall, serum HBV DNA
levels continuously declined, and the overall mean
changes at months 3, 6 and 12 were −4.26 log10 IU/mL,
−4.89 log10 IU/mL and −5.12 log10 IU/mL, respectively
(Fig. 1a). The mean reduction in serum HBV DNA levels
from baseline to month 12 was similar in the ETV and
TDF groups (−5.01 vs.−5.22 log10 IU/mL, P = 0.559) using
a repeated measure analysis (Fig. 1b). During the first year
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of therapy, VR (HBV DNA levels < 20 IU/mL) and primary
non-response were observed in 161 (76.7%) and 0 patients
(0%), respectively. One hundred fifty of 184 patients who
had shown elevated serum ALT levels at baseline achieved
a normalization of serum ALT levels (81.5%). During the
first year of therapy, HBeAg loss/seroconversion occurred
in 18 of 121 (14.9%) HBeAg-positive patients.
There were no significant differences in the virologic,
serologic and biochemical responses at year 1 between
two groups (Table 2). The mean reduction in serum
HBV DNA levels from baseline to month 12 was similar
between the ETV and TDF groups (−5.54 vs.−5.78 log10
IU/mL, P = 0.159), even in the HBeAg-positive patients
(Fig. 2a). Although HBV DNA levels were more strongly
suppressed by TDF than by ETV (−5.92 vs. −5.78 log10
IU/mL, P = 0.022) in the HBeAg-positive subgroup with
higher HBV DNA levels (Fig. 2b), the type of antiviral
used was not an independent factor for VR. During the
mean long-term therapy period of 25.3 months, the viro-
logic and serologic responses were additionally achieved
in 22 and 10 patients, respectively. Persistent viremia
was observed in 26 patients, consisting of 17 patients
(16.2%, 17/105) in the ETV group and 9 patients (8.6%,
9/105) in the TDF group.
The cumulative VR rates at 3, 6, 12, 24 and 36 months
were 20%, 54%, 79%, 86% and 91%, respectively, during the
follow-up period (Fig. 3a). The cumulative VR rates in the
ETV group at 3, 6, 12, 24 and 36 months were 21%, 55%,
75%, 84% and 87%, respectively, whereas, in the TDF group,
the rates at 3, 6, 12, 24 and 36 months were 19%, 52%, 83%,
91% and 94%, respectively. These differences were not
significant (Fig. 3b, P = 0.222). The cumulative VR rates in
the HBeAg-negative subgroup also showed no significant
difference between the ETV and TDF groups (89%, 96%
and 100% vs. 76%, 98% and 100% at 6, 12 and 24 months,
respectively, P = 0.819). However, in the HBeAg-positive
subgroup, the cumulative VR rates in the ETV group at 6,
12, 24 and 36 months were 28%, 57%, 70% and 77%, re-
spectively, whereas the rates in the TDF group at 6, 12, 24
and 36 months were 37%, 73%, 84% and 91%, respectively,
with significant difference between two groups (P = 0.035,
Fig. 3c). This finding was conspicuous in another subgroup
of HBeAg-positive CHB with higher HBV DNA levels
(20%, 53%, 68% and 68% at 6, 12, 24 and 36 months in
ETV group vs. 32%, 71%, 83% and 90% at 6, 12, 24 and
36 months in TDF group, respectively, P = 0.012, Fig. 3d).
Predictive factors for virologic response
A multivariate logistic regression model was used to iden-
tify the independent risk factors significantly associated






Age (years) 47.0 ± 12.0 45.5 ± 11.9 0.396
Sex (male, %) 64 (61.0) 67 (63.8) 0.776















Serum ALT (IU/L) 179.5 ± 253.0 232.3 ± 427.7 0.278
Serum total
bilirubin (mg/dL)
1.20 ± 1.74 1.06 ± 1.29 0.507
Serum albumin (g/dL) 4.11 ± 0.56 4.10 ± 0.53 0.905
INR 1.12 ± 0.19 1.11 ± 0.17 0.927
Serum HBV DNA level
(log10 IU/mL)
6.56 ± 1.33 6.66 ± 1.26 0.564
Duration of follow-up
(months)
27.0 ± 7.2 23.6 ± 5.2
Continuous variables were expressed as mean ± standard deviation
ALT alanine aminotransferase, CHB chronic hepatitis B, ETV entecavir, HBeAg
hepatitis B e antigen, HBV hepatitis B virus, INR international normalized ratio,
LC liver cirrhosis, MELD model for end stage liver disease, TDF tenofovir
Fig. 1 Change of HBV DNA during follow-up period. a The changes in the mean hepatitis B virus (HBV) DNA levels from baseline through week
48. The overall mean changes at weeks 12, 24 and 48 were −4.26 log10 IU/mL, −4.89 log10 IU/mL and −5.12 log10 IU/mL, respectively. b The mean
reduction in serum HBV DNA levels from baseline to week 48 was similar in tenofovir and entecavir group (−5.22 vs. −5.01 log10 IU/mL, P = 0.559)
by repeated measure analysis
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with VR during the first year. In a univariate analysis,
disease status (CHB vs. cirrhosis), HBeAg status,
serum HBV DNA levels and IVR-3 were candidate
variables for the multivariate analysis. Of the clinical
features, cirrhosis, HBeAg negativity, low serum HBV
DNA levels and IVR-3 were considered favorable fac-
tors for VR, while other factors, including the type of
antiviral used (ETV vs. TDF), were not significantly
associated with VR (Table 3). In the multivariate ana-
lysis, only IVR-3 remained independent predictors for
one year VR (Table 4).
A cox proportional hazards model was used to identify
the independent factors for long-term VR. In the multi-
variate analysis, HBeAg status, serum HBV DNA levels
and IVR-3 were identified as predictive factors for long-
term VR (Table 5).
Predictive factors on the long-term efficacy
Sixty seven patients (31.9%) had low baseline serum HBV
DNA levels (<6 log10 IU/mL), 173 patients (82.4%) showed
IVR-3 and 89 patients (42.4%) were negative for HBeAg.
The patients with low serum HBV DNA levels, IVR-3 or
HBeAg negativity had a significantly higher probability of
achieving a VR. In patients with low baseline serum HBV
DNA levels, the cumulative VR rates were 84%, 94%, 97%
and 100% at 6, 12, 24 and 36 months, which were in
contrast with the rates, 40%, 72%, 80% and 83% in patients
with high baseline serum HBV DNA levels (P < 0.001,
Fig. 4a). The cumulative VR rates were 64%, 89%, 94% and
100% in patients with IVR-3 and 5%, 32%, 46% and 51% in
patients without IVR-3 at 6, 12, 24 and 36 months,
respectively (P <0.001, Fig. 4b). A similar pattern was
observed according to HBeAg status (P < 0.001).
Table 2 Virologic, serologic and biochemical response at week 48
Baseline Week 24 Week 48 Total P
Mean HBV DNA (log10 IU/mL) 6.61 1.72 1.49 5.12↓ 0.559
ETV (n = 105) 6.56 1.80 1.55 5.01↓
TDF (n = 105) 6.66 1.64 1.44 5.22↓
HBV DNA negativity by PCR 161(76.7%) 0.192
ETV (n = 105) 58 (55.2%) 76 (72.4%)
TDF (n = 105) 56 (53.3%) 85 (81.0%)
HBeAg loss/seroconversion 18 (14.9%) 0.452
ETV (n = 58) 7 (12.1%)
TDF (n = 63) 11 (17.5%)
Biochemical response 150 (81.5%) 0.647
ETV (n = 92) 77 (83.7%)
TDF (n = 92) 73 (79.3%)
Data are expressed mean or number
ETV entecavir, HBeAg hepatitis B e antigen, HBV hepatitis B virus, TDF tenofovir
Fig. 2 Change of HBV DNA in HBeAg-positive patients. a The mean reduction in serum hepatitis B virus (HBV) DNA levels from baseline to month
12 was similar in tenofovir and entecavir group (−5.88 vs. −5.54 log10 IU/mL, P = 0.159) in the hepatitis e antigen (HBeAg) positive patients. b
Serum HBV DNA levels were more strongly suppressed by tenofovir than entecavir (−5.92 vs. −5.78 log10 IU/mL, P = 0.022) in the HBeAg-positive
patients with a higher HBV DNA levels
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Virologic breakthrough during long-term therapy
VBT was experienced in 13 patients, with cumulative
rates of 1%, 4% and 11% at 12, 24 and 36 months, re-
spectively. There was no significant difference in the cu-
mulative rates between the ETV and TDF groups (2%,
5% and 12% vs. 1%, 4% and 7% at 12, 24 and 36 months,
respectively, P = 0.333). VBT developed in 9 cases in the
ETV group and in 4 cases in the TDF group. The major-
ity (11/13, 85%) of VBT was related to medication ad-
herence. As expected, mutations associated with drug
resistance were detected in 2 patients in the ETV group
(L180M+ M204V + S202G).
Adverse effects
No serious adverse effects such as lactic acidosis or in-
crease in serum creatinine levels were reported in any of
the patients in either treatment group. No adverse ef-
fects leading to discontinuation of therapy occurred dur-
ing the whole treatment period. During the follow-up
period, 6 patients (5.7%) in TDF group and 7 (6.7%) in
ETV group were diagnosed with HCC. The incidence of
HCC according to the type of treatment was not differ-
ent. All of them except two patients were already cir-
rhotic patients before antiviral treatment, the patients
diagnosed with HCC were significantly older than with-
out HCC at the beginning of antiviral treatment (54.2 ±
8.5 vs. 45.7 ± 12.0, P = 0.014).
Discussion
The risk of cirrhosis and/or HCC in CHB increases pro-
portionally as serum HBV DNA levels increase [5, 6].
This finding suggests that sustained suppression of HBV
replication with anti-HBV therapy may successfully pre-
vent the progression of chronic liver diseases. Thus, the
suppression of HBV replication should be considered
the most important therapeutic goal for CHB patients in
clinical settings. Currently, ETV and TDF are the most
commonly used HBV drugs due to their excellent po-
tency and higher genetic barrier. However, there is lim-
ited information on the comparative efficacy of these
drugs, and only one drug-to-drug comparison study has
been conducted thus far [19]. Although there have been,
Fig. 3 Cumulative virologic response (VR) rate. a Cumulative VR rates at 3, 6, 12, 24 and 36 months were 20%, 54%, 79%, 86% and 91%,
respectively. b Cumulative VR rates were not significant different between the two groups (P = 0.222). c Cumulative VR rates of tenofovir group
were higher than those of entecavir group, in the hepatitis B e antigen (HBeAg) positive patients. d The difference of cumulative VR rates was
more evident in HBeAg-positive patients with a higher hepatitis B virus DNA levels (>6 log10 IU/mL)
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so far, a few studies evaluating the efficacy of ETV and
TDF in treatment-naïve CHB, they included only a lim-
ited number of patients or only showed a short-term ef-
ficacy [20–25]. Futhermore, most previous studies were
retrospective and not randomized, some of them showed
different baseline characteristics-such as age, gender or
liver disease severity. The present study was also not a
randomized controlled trial, but the limitation was com-
plemented by using propensity score. The present study
enrolled an adequate number of the treatment-naïve
CHB patients and followed these patients for a sufficient
time period (up to 39 months) to directly compare the
efficacy between ETV and TDF. Of note, in this study,
the majority of patients had a VR over 90% after
36 months of therapy. Among HBeAg-positive patients,
the cumulative VR rates at month 12 in our study (75%
in ETV and 83% in TDF) are comparable with previous
global multicenter trials of 67% and 76%, respectively.
These results were also comparable in HBeAg-negative
patients (97% vs. 90% in ETV; 98% vs. 93% in TDF, re-
spectively) [9, 10, 12].
In this study, ETV and TDF showed similar overall anti-
viral efficacy both for one year and during the long-term
follow-up. These results were similar to previous studies
[21–23, 25]. However, our subgroup analysis indicated that
TDF was significantly better than ETV for suppressing HBV
DNA in HBeAg-positive patients, especially with higher
HBV DNA levels. There were a few studies which TDF
showed more potent antiviral efficacy than ETV in HBeAg-
positive patients [24, 26]. When comparing our study with
these previous studies, the present study included only
treatment-naïve patients and who had been adherent to
medication therapy for at least one year. Patient adherence
may contribute to achieve comparable overall VR at month
12 and during long-term period in both groups.
Another interesting finding in the present study is the
prognostic role of IVR-3, which is a good predictive factor
for both short-term and long-term VR. Higher baseline
ALT, lower HBV DNA levels and HBeAg-negative status
are already well known to be associated with VR. In
addition to these factors, our finding suggested that IVR-3
was also able to predict VR very well. In fact, cumulative
VR rates in patients achieving IVR-3 was significantly
higher than in patients without IVR-3 (100% vs. 51% at
36 months, RR 3.403, 95% CI 1.977–5.849, P < 0.001).
Surprisingly, the predictive value of IVR-3 was much higher
than those of previously known factors, such as HBeAg sta-
tus and HBV DNA levels. Pragmatically, IVR-3 combined
with HBeAg and HBV DNA levels may help to predict
Table 3 Comparison of clinical features between the groups according to one year virologic response





Age (years) 46.8 ± 11.0 44.4 ± 14.7 0.285
Sex (male, %) 99 (61.5) 32 (65.3) 0.737













Serum ALT (IU/L) 198.0 ± 305.7 231.8 ± 475.0 0.557
Serum total bilirubin (mg/dL) 1.12 ± 1.46 1.19 ± 1.77 0.774
Serum albumin(g/dL) 4.10 ± 0.53 4.11 ± 0.60 0.952
INR 1.12 ± 0.17 1.09 ± 0.21 0.319
IVR-3 (−/+) 12/149(7.5/92.5) 25/24 (51.0/49.0) <0.001
Serum HBV DNA level (log10 IU/mL) 6.30 ± 1.23 7.61 ± 0.97 <0.001
Treatment regimens 0.192
ETV (n = 105, %) 76 (72.4) 29 (27.6)
TDF (n = 105, %) 85 (81.0) 20 (19.0)
Data are expressed as mean ± standard deviation or number
ALT alanine aminotransferase, CHB chronic hepatitis B, ETV entecavir, HBeAg hepatitis B e antigen, HBV hepatitis B virus, INR international normalized ratio, IVR-3
initial virologic response at 3 months, LC liver cirrhosis, MELD model for end stage liver disease, TDF tenofovir, VR virologic response
Table 4 Multivariate analyses of clinical factors affecting one
year virologic response
Factors RR 95% CI P
Disease status (CHB/LC) 0.559 0.205–1.521 0.255
IVR-3 (+/−) 6.214 2.500–15.443 <0.001
HBeAg (−/+) 3.184 0.977–10.377 0.055
Serum HBV DNA level (log10 IU/mL) 0.605 0.357–1.023 0.061
RR, relative risk, 95% CI 95% confidence interval, CHB chronic hepatitis B,
HBeAg hepatitis B e antigen, HBV hepatitis B virus, IVR-3 initial virologic
response at 3 months, LC liver cirrhosis
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long-term VR and determine whether to maintain primary
therapy or switch to other regimens.
Multi-center, long-term studies using ETV and/or TDF
have shown excellent safety and tolerance with little anti-
viral resistance (1.2% in ETV and 0% in TDF up to 5 years).
In our study, there was no serious clinical adverse reaction
in the two treatment groups. However, even though the
patient had achieved VR, HCC was developed in 5.7% of
patients receiving TDF and 6.7% of ETV. Considering the
risk of developing HCC is appears to be greatest among
individuals with the highest serum HBV DNA levels, the
introduction of nucleos(t)ide analogues has contributed to
reduce the risk of HCC. The reason why the incidence of
HCC was higher than previous studies was that the
present study included a large number of cirrhotic pa-
tients. Cirrhosis has been well known risk factor for HCC.
Actually, all patients diagnosed with HCC in this study
were cirrhotic patients, except two patients. Our finding
confirmed that old and cirrhotic patients should be
carefully undergone surveillance for HCC regardless of
achieving VR.
It should be considered that poor medication adherence is
a major cause of suboptimal response and/or VBT that tends
to be increasingly prevalent in proportion to the duration of
therapy [27–31]. In the current study, overall cumulative
VBT rates were 1%, 4% and 11% at 12, 24 and 36 months, re-
spectively, which was primarily related to medication adher-
ence. Only two patients showed resistance in the ETV group.
Table 5 Factors associated with long-term virologic response
Factors Univariate analysis Multivariate analysis
RR 95% CI P RR 95% CI P
Age (years) 1.007 0.995–1.018 0.262
Sex (female/male) 1.009 0.747–1.363 0.952
HBeAg-positive (−/+) 3.031 2.209–4.158 <0.001 1.834 1.246–2.698 0.002
Disease status (LC/CHB) 1.577 1.172–2.121 0.003 1.028 0.748–1.411 0.867
MELD (<7/≥7) 0.923 0.676–1.260 0.613
INR 1.020 0.469–2.218 0.961
Serum ALT (IU/L) 1.000 1.000–1.000 0.890
Serum total bilirubin (mg/dL) 1.005 0.918–1.101 0.908
Serum albumin (g/dL) 1.077 0.824–1.406 0.588
IVR-3 (+/−) 4.851 2.902–8.109 <0.001 3.403 1.977–5.859 <0.001
Serum HBV DNA level
(log10 IU/mL)
0.638 0.569–0.715 <0.001 0.817 0.696–0.958 0.013
Therapy regimens (TDF/ETV) 1.162 0.868–1.555 0.313
RR relative risk, 95% CI 95% confidence interval, ALT alanine aminotransferase, CHB chronic hepatitis B, ETV entecavir, HBeAg hepatitis B e antigen, HBV hepatitis B
virus, INR international normalized ratio, IVR-3 initial virologic response at 3 months, LC liver cirrhosis, MELD model for end stage liver disease, TDF tenofovir
Fig. 4 Cumulative virologic response (VR) rate according to HBV DNA levels and IVR-3. a Cumulative VR rates in the patients with high baseline
serum HBV DNA levels at 6, 12, 24 and 36 months were 40%, 72%, 80% and 83%, respectively. They were 84%, 94%, 97% and 100%, respectively,
in the patients with low baseline serum HBV DNA levels. b Cumulative VR rates in the patients without IVR-3 at 6, 12, 24 and 36 months were 5%,
32%, 46% and 51%, respectively. And in the patients with IVR-3, they were 64%, 89, 94 and 100%, respectively
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Our study has some limitations. First, the study was
retrospective and non-randomized. However, we adjusted
this shortcoming by using propensity score to minimize
the influence of the baseline characteristics. This process
made our outcomes to be more reliable. Second, in the
process of matching the patients, the sample size was de-
creased and the follow-up period was shortened. Never-
theless, each group included over 100 patients and the
follow-up period was up to 39 months. This is comparable
with the most recently published, randomized controlled
trial to compare treatment efficacy of ETV and TDF in
treatment-naïve CHB patients [32]. Third, the study may
not be generalizable to other ethnic groups because we in-
cluded only Asian patients (Koreans) who were infected
by mainly HBV genotype C.
To date, randomized controlled or well matched com-
parative studies regarding the efficacy of TDF or ETV in
treatment-naïve CHB patients were very rare. Therefore, it
is necessary to conduct direct comparisons of a prospective
nature with larger numbers of patients and longer period of
treatment.
Conclusions
TDF and ETV showed comparable efficacy and safety during
3 years in treatment-naïve CHB patients. We found that
IVR-3 was predictive factor on long-term efficacy in addition
to HBV DNA levels and HBeAg status. The present study
suggested that TDF might be the more potent option in a
subgroup of HBeAg-positive CHB, especially with higher
HBV DNA levels. VBT occurred with similar rates in both
groups, and was primarily the result of medication nonad-
herence. Old and cirrhotic patients should be carefully
undergone surveillance for HCC regardless of achieving VR.
Abbreviation
ALT: Alanine aminotransferase; anti-HBe: Antibody to hepatitis B e antigen;
anti-HBs: Antibody to hepatitis B surface antigen; CHB: Chronic hepatitis B;
ETV: Entecavir; HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B surface antigen;
HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; IVR-3: Initial virologic response




The authors who have taken part in this study declare that they do not have
anything to disclose regarding funding. No grants or financial support were
received for this study.
Availability of data and materials
The datasets during the current study are available from corresponding
author on reasonable request.
Authors’ contributions
HSK, DJK and CKP designed the study. JWP, SEK, MSL, SHP and KTS carried
out the extraction of data. KMK, MKJ and HSK carried out the statistical
analysis of studies. JWP wrote the paper. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not Applicable.
Ethics approval and consent to participate
The study protocol was approved by the Hallym University Medical Center
Institutional Review Boards (IRB No. 13-1-49). The ethical committee waived
the need for a written informed consent because this study was performed
retrospectively.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Internal Medicine, Hallym University Sacred Heart Hospital of
Hallym University Medical Center, 22, Gwanpyeong-ro 170 beon-gil,
Dongan-gu, Anyang-si, Gyeonggi-do 14068, Republic of Korea. 2Department
of Biomedical Gerontology, Graduate School of Hallym University, 1
Hallymdaehak-gil, Chuncheon-si, Gangwon-do 24252, Republic of Korea.
3Department of Occupational and Environmental Medicine, Hallym University
Sacred Heart Hospital of Hallym University Medical Center, 22,
Gwanpyeong-ro 170 beon-gil, Dongan-gu, Anyang-si, Gyeonggi-do 14068,
Republic of Korea. 4Department of Environmental Health, Seoul National
University School of Public Health, 1, Gwanak-ro, Gwanak-gu, Seoul 08826,
Republic of Korea. 5Department of Internal Medicine, Kangdong Sacred Heart
Hospital of Hallym University Medical Center, 18, Cheonho-daero 173-gil,
Gangdong-gu, Seoul 05355, Republic of Korea. 6Department of Internal
Medicine, Chuncheon Sacred Heart Hospital of Hallym University Medical
Center, 77, Sakju-ro, Chuncheon-si, Gangwon-do 24253, Republic of Korea.
7Department of Internal Medicine, Kangnam Sacred Heart Hospital of Hallym
University Medical Center, 1, Singil-ro, Yeongdeungpo-gu, Seoul 07441,
Republic of Korea.
Received: 29 September 2016 Accepted: 1 March 2017
References
1. Safileas M, Lyqidakis NJ, Manti C. Hepatitis B today. Hepatogastroenterology.
2007;54:545–8.
2. Lavanchy D. Hepatitis B, virus epidemiology, disease burden, treatment, and
current and emerging prevention and control measures. J Viral Hepat.
2004;11:97–107.
3. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular
carcinoma. Clin Liver Dis. 2005;9:191–211.
4. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology.
2009;50:661–2.
5. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular
carcinoma across a biological gradient of serum hepatitis B virus DNA level.
JAMA. 2006;295:65–73.
6. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk
based on the level of circulating hepatitis B viral load. Gastroenterology.
2006;130:678–86.
7. Liaw YF. Hepatitis B, virus replication and liver disease progression: the
impact of antiviral therapy. Antivir Ther. 2006;11:669–79.
8. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term
entecavir therapy results in the reversal of fibrosis/cirrhosis and continued
histological improvement in patients with chronic hepatitis B. Hepatology.
2010;52:886–93.
9. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A
comparison of entecavir and lamivudine for HBeAg-positive chronic
hepatitis B. N Engl J Med. 2006;354:1001–10.
10. Lai CL, Shouval D, Lok AS, Chang TT, Cheinguer H, Goodman Z, et al.
Entecavir versus lamivudine for patients with HBeAg-negative chronic
hepatitis B. N Engl J Med. 2006;354:1011–20.
11. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, et al. Early
hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients
with chronic hepatitis B: A randomized international study of entecavir
versus adefovir. Hepatology. 2009;49:72–9.
12. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al.
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis
B. N Engl J Med. 2008;359:2442–55.
Park et al. BMC Gastroenterology  (2017) 17:39 Page 8 of 9
13. European Association for the Study of the Liver. EASL clinical practice
guidelines: management of chronic hepatitis B virus infection. J Hepatol.
2012;57:167–85.
14. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al.
Long-term monitoring shows hepatitis B virus resistance to entecavir in
nucleoside-naïve patients is rare through 5 years of therapy. Hepatology.
2009;49:1503–14.
15. Kitrinos KM, Corsa A, Liu Y, Flasherty J, Snow-Lampart A, Marcellin P, et al.
No detectable resistance to tenofovir disoproxil fumarate after 6 years of
therapy in patients with chronic hepatitis B. Hepatology. 2014;59:434–42.
16. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues.
Gastroenterology. 2009;137:1593–608.
17. Park JW, Kim HS, Seo DD, Jang JS, Shin WG, Kim KH, et al. Long-term
efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with
prior lamivudine resistance. J Viral Hepat. 2011;18:e475–81.
18. Lee JM, Kim HJ, Park JY, Lee CK, Kim DY, Kim JK, et al. Rescue monotherapy
in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B:
adefovir versus entecavir. Antivir Ther. 2009;14:705–12.
19. Murat K, Fatma S, Yesim A, Nail O, Ahmet TE, Deniz S. Head-to-head
comparison of two years efficacy of entecavir and tenofovir in patients with
treatment-naïve chronic hepatitis B-The real life data.
Hepatogastroenterology. 2015;62:982–6.
20. Ha NB, Trinh HN, Rosenblatt L, Nghiem D, Nguyen MH. Treatment
outcomes with first-line therapies with entecavir and tenofovir in treatment-
naive chronic hepatitis B patients in a routine clinical practice. J Clin
Gastroenterol. 2016;50:169–74.
21. Idilman R, Gunsar F, Koruk M, Keskin O, Meral CE, Gulsen M, et al. Long-term
entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic
hepatitis B patients in the real-world setting. J Viral Hepat. 2015;22:504–10.
22. Batirel A, Guclu E, Arslan F, Kocak F, Karabay O, Ozer S, et al. Comparable
efficacy of tenofovir versus entecavir and predictors of response in
treatment-naïve patients with chronic hepatitis B: a multicenter real-life
study. Int J Infect Dis. 2014;28:153–9.
23. Ozaras R, Mete B, Ceylan B, Ozgunes N, Gunduz A, Karaosmanoglu H, et al.
First-line monotherapies of tenofovir and entecavir have comparable efficacies
in hepatitis B treatment. Eur J Gastroenterol Hepatol. 2014;26:774–80.
24. Gao L, Trinh HN, Li J, Nguyen MH. Tenofovir is superior to entecavir for
achieving complete viral suppression in HBeAg-positive chronic hepatitis B
patients with high HBV DNA. Aliment Pharmacol Ther. 2014;39:629–37.
25. Doğan ÜB, Kara B, Gümürdülü Y, Soylu A, Akin MS. Comparison of the
efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive
patients with chronic hepatitis B. Turk J Gastroenterol. 2012;23:247–52.
26. López Centeno B, Collado Borrell R, Pérez Encinas M, Gutiérrez García ML,
Sanmartin FP. Comparison of the effectiveness and renal safety of tenofovir
versus entecavir in patients with chronic hepatitis B. Farm Hosp. 2016;40:279–86.
27. Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana RJ, Marrero JA,
Licari T, et al. Virological breakthrough and resistance in patients with
chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
Hepatology. 2011;53:1854–63.
28. Sogni P, Carrieri MP, Fontaine H, Mallet V, Vallet-Pichard A, Trabut JB, et al.
The role of adherence in virological suppression in patients receiving anti-
HBV analogues. Antivir Ther. 2012;17:395–400.
29. Chotiyaputta W, Hongthanakorn C, Oberhelman K, Fontana RJ, Licari T, Lok AS.
Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice
and correlation with virological breakthroughs. J Viral Hepat. 2012;19:205–12.
30. Kamezaki H, Kanda T, Arai M, Wu S, Nakamoto S, Chiba T, et al. Adherence
to medication is a more important contributor to viral breakthrough in
chronic hepatitis B patients treated with entecavir than in those with
Lamivudine. Int J Med Sci. 2013;10:567–74.
31. Chien RN, Peng CY, Kao JH, Hu TH, Lin CC, Hu CT, et al. Higher adherence
with 3-year entecavir treatment than lamivudine or telbivudine in
treatment-naive Taiwanese patients with chronic hepatitis B. J Gastroenterol
Hepatol. 2014;29:185–92.
32. Sriprayoon T, Mahidol C, Ungtrakul T, Chun-On P, Soonklang K, Pongpun W,
et al. Efficay and safety of entecavir versus tenofovir treatment in chronic
hepatitis B patients: A randomized controlled trial. Hepatol Res. 2016. doi:
10.1111/hepr.12743.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Park et al. BMC Gastroenterology  (2017) 17:39 Page 9 of 9
